TENELISIGN 20 Tablet is an oral antidiabetic medication that contains Teneligliptin Hydrobromide Hydrate 20 mg as its active ingredient. Teneligliptin belongs to the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class of drugs and is primarily used for the management of type 2 diabetes mellitus in adults. It plays a significant role in achieving and maintaining optimal blood glucose levels, especially in patients who are unable to control their diabetes through diet and exercise alone.

Teneligliptin works by inhibiting the DPP-4 enzyme, which is responsible for breaking down incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones are naturally released after eating and help regulate glucose levels by increasing insulin secretion from the pancreas and decreasing glucagon release. By prolonging the activity of incretins, TENELISIGN 20 enhances the body’s own ability to control blood sugar, particularly after meals, thereby reducing both fasting and postprandial blood glucose levels.

TENELISIGN 20 can be used as monotherapy or in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin, depending on the individual needs of the patient. It is especially useful in patients who are at risk of hypoglycemia or weight gain, as it provides effective glycemic control with a low risk of hypoglycemia and neutral effect on body weight. The usual dosage is one tablet daily, taken with or without food, and should be taken at the same time every day to maintain consistent therapeutic levels in the blood.

This medication is generally well-tolerated. However, some patients may experience mild side effects, including headache, upper respiratory tract infections, sore throat, or gastrointestinal discomfort. These symptoms are usually transient and do not require discontinuation. In rare cases, patients may experience pancreatitis, hypersensitivity reactions, or joint pain, and should seek medical attention if such symptoms arise. It is important to undergo periodic monitoring of blood glucose, kidney function, and liver enzymes while on this medication, especially in patients with pre-existing conditions.

TENELISIGN 20 is not intended for use in type 1 diabetes or diabetic ketoacidosis. It should be used with caution in patients with severe renal impairment, although it is generally considered safe in mild to moderate renal dysfunction. The drug has a favorable pharmacokinetic profile with a long half-life, allowing for once-daily dosing and consistent control of glucose levels over 24 hours.

During clinical use, it has been shown to significantly reduce HbA1c levels, the marker of long-term blood sugar control, making it an effective choice for chronic management. TENELISIGN 20 may also provide added cardiovascular benefits, although long-term studies are still ongoing to evaluate its protective effects on the heart and blood vessels.

This product is manufactured under strict quality standards, including WHO-GMP and ISO-certified processes. Production adheres to Good Manufacturing Practices (GMP) and global regulatory norms to ensure safety, efficacy, and consistency across all batches. Each tablet is formulated for optimal bioavailability, ensuring that patients receive the intended therapeutic benefits with every dose.